Q-omics provides the consensus-scored ARMCX2 profile across patient tissues and cancer cell-line models. ARMCX2 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in UCS. Among the 18 cancer types available for tumor–normal comparison, ARMCX2 is differentially expressed in 12, with the highest sampling consensus in UCEC. Additionally, ARMCX2 RNA expression shows 18,242 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight UCS, UCEC, and THYM as cancer lineages where ARMCX2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ARMCX2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ARMCX2 survival associations across molecular data types. ARMCX2 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (7) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ARMCX2 RNA expression–survival associations across cancer types. High ARMCX2 expression shows unfavorable associations in STAD, LGG and CESC, but favorable associations in UCS, KIRC and MESO. The UCS Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .002). Together, the overview and detailed table identify UCS as the clearest survival context for ARMCX2 RNA expression.
This table summarizes ARMCX2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 6. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for ARMCX2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ARMCX2 shows lower tumor expression in UCEC, KIRC, KICH, BLCA and KIRP and higher tumor expression in CHOL. The UCEC box plot shows higher ARMCX2 RNA expression in normal versus tumor tissue (log2 FC = −1.372, t-test p = .005).
This table shows molecular features associated with ARMCX2 in patient tissues and cancer cell lines. In patient samples, ARMCX2 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, ARMCX2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in CNS and LARGE_INTESTINE.
